首页> 外文期刊>The Antitrust Bulletin >Mergers and Innovation
【24h】

Mergers and Innovation

机译:合并与创新

获取原文
获取原文并翻译 | 示例
           

摘要

Do mergers raise substantial additional issues when the parties have significant innovation programs? To answer this, we examine the merger-related efficiencies that arise only with substantial innovation, arguing that innovation-intensive mergers should be treated more leniently than mergers without this dynamic dimension. We provide guidance on evidence that might determine the magnitude of such efficiencies. Next, we argue that where innovation is “directed” towards a product market, dealing with product line overlap should allay concerns about postmerger innovation. If research is not directed, we argue that theories of harm linked to the product market are unconvincing. Instead, one should look at theories of harms in the innovation market, which stem from the advantage in being first to innovate. Such first-mover advantages can be rooted in patent protection, switching costs, or network effects. This approach helps explain some of the remedies recently imposed on transactions such as Dow-Dupont and Bayer-Monsanto.
机译:当双方具有重大创新计划时,合并是否会引发其他实质性问题?为了回答这个问题,我们研究了只有实质性创新才能产生的与合并相关的效率,并认为与没有这种动态维度的并购相比,创新密集型并购应得到更宽大的对待。我们为可能确定这种效率的大小的证据提供指导。接下来,我们认为,在将创新“导向”产品市场的情况下,处理产品线重叠应该减轻对合并后创新的担忧。如果不进行研究,我们认为与产品市场有关的损害理论是没有说服力的。取而代之的是,应该研究创新市场中损害的理论,这些理论源于首先进行创新的优势。这样的先发优势可以植根于专利保护,交换成本或网络效应。这种方法有助于解释最近对道琼斯-杜邦公司和拜耳-孟山都公司等交易采取的一些补救措施。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号